TrialMultiple sclerosis (Houndmills, Basingstoke, England)2022

Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study.

Amit Bar-Or et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.